Biotech is going to break out, RBC Capital Markets' Michael Yee said. There are the names on his buy list.» Read More
Regeneron Pharmaceuticals Inc, which signed a deal with Pennsylvania's Geisinger Health System in January 2014 to sequence partial genomes of some 250,000 volunteers, is already claiming discoveries based on the new approach. Pfizer Inc, Roche Holding AG and Biogen Inc are working on similar projects that use DNA and patient health data to find new drug...
Take a look at some of Tuesday's after-hours buzz: American Express, Vertex & more
The next takeout target in biotech? Here are three eligible candidates
*FDA slated to make decision on treatment on July 5. FDA questioned whether Vertex Pharmaceuticals Inc's experimental combination therapy for cystic fibrosis had an added benefit over the company's already approved therapy, Kalydeco, in patients with the most common genetic mutation behind the deadly disease. The FDA is slated to make a decision on Orkambi...
May 8- Vertex Pharmaceuticals Inc's combination of an experimental compound and an approved drug significantyly improved lung function in cystic fibrosis patients with the most common genetic mutation underlying the disease, FDA staff said. The FDA is trying to ask the panel if the evidence is enough to show that the combination's benefit is significantly...
May 8- FDA staff reviewers questioned whether Vertex Pharmaceuticals Inc's experimental cystic fibrosis drug added any benefit over its already approved therapy, Kalydeco, in patients with the most common genetic mutation underlying the disease. Vertex is seeking approval for the combination of the compound lumacafotor and Kalydeco to treat CF patients...
May 4- Corbus Pharmaceuticals Holdings Inc's experimental drug for cystic fibrosis, a rare lung-scarring disease, could be a real money spinner and pose a challenge to rival Vertex Pharmaceuticals Inc's successful treatment, Kalydeco. Corbus, a tiny biopharmaceutical company, received $5 million from the Cystic Fibrosis Foundation last month to develop...
Brian Sullivan and Dom Chu will list the top 40 cheapest stock picks from Goldman Sachs.
Earnings season is almost here for most companies. But others are hurtling straight into loss season. USA Today reports.
President Obama will dedicate $215 million in his budget request to a program that will target the underlying cause of disease.
The heads of research at several large drugmakers have received mysterious invitations to the White House for a meeting Friday morning.
The JPMorgan health care conference hadn't even officially begun when the first big piece of news of the week hit: Irish drugmaker Shire said Sunday morning it's purchasing orphan-drug company NPS Pharmaceuticals for $5.2 billion.
Some of Wednesday's midday movers:
U.S. Treasury yields continued to rise on Tuesday amid data and expectations of Fed action.
Health care has been on a tear in 2014, and there is still room for upside. Wall Street analysts are focusing on the following four trends.
Some of Monday's midday movers:
Stocks cut losses to close mixed on Thursday as geopolitical tensions lingered ahead of consumer data.
U.S. stocks closed higher for the third time in four days as a rally in tech, airlines and biotech firms helped lead gains.
Pfizer's vulnerability to cheap generics and its weak roster of experimental medicines will be on display Tuesday, when the company reports earnings.
The liver disease NASH is becoming more widespread, and the market for treatments may rival those for hepatitis C.